NASDAQ:ARRY - Array Biopharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$22.92 +0.60 (+2.69 %)
(As of 04/23/2019 04:00 PM ET)
Previous Close$22.32
Today's Range$22.16 - $22.9980
52-Week Range$12.56 - $25.05
Volume2.19 million shs
Average Volume3.26 million shs
Market Capitalization$5.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The company's lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including a Phase III trial in BRAF-mutant colorectal cancer. Its product pipeline also includes ipatasertib, an AKT inhibitor that is in Phase III trial to treat prostate or breast cancers; selumetinib, a MEK inhibitor for cancer; larotrectinib, a PanTrk inhibitor that is in a Phase II/registration clinical trial for cancer; tucatinib, a HER2 inhibitor for breast cancer, which is in Phase II/registration trial; and ARRY-797 that is in Phase III clinical trial for Lamin A/C-related dilated cardiomyopathy. In addition, the company is developing varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric cancer; ARRY-382, a CSF1R inhibitor that is in Phase II clinical trial to treat cancer; motolimod/VTX-2337, a Toll-like receptor that is in Phase II clinical trial for cancer; and prexasertib/LY2606368, a CHK-1 inhibitor, which is in multiple Phase I or II clinical trials for cancer. Further, its drug candidates in Phase I clinical trials include GDC-0575, a CHK-1 inhibitor for cancer; LOXO-292, a RET inhibitor to treat cancer; and LOXO-195, a Trk inhibitor for cancer. Additionally, its drug candidates include Ganovo/danoprevir, a protease inhibitor for hepatitis C virus. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Receive ARRY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARRY
CUSIP04269X10
Phone303-381-6600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$173.77 million
Book Value$1.04 per share

Profitability

Net Income$-147,340,000.00

Miscellaneous

Employees298
Market Cap$5.00 billion
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable

Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions

What is Array Biopharma's stock symbol?

Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array Biopharma's earnings last quarter?

Array Biopharma Inc (NASDAQ:ARRY) released its quarterly earnings results on Tuesday, February, 5th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.11. The biopharmaceutical company earned $82.55 million during the quarter, compared to the consensus estimate of $52.44 million. Array Biopharma had a negative return on equity of 44.37% and a negative net margin of 46.20%. The business's revenue was up 95.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.17) EPS. View Array Biopharma's Earnings History.

When is Array Biopharma's next earnings date?

Array Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Array Biopharma.

What price target have analysts set for ARRY?

10 brokerages have issued 1-year price objectives for Array Biopharma's stock. Their forecasts range from $20.00 to $33.00. On average, they expect Array Biopharma's stock price to reach $26.7778 in the next twelve months. This suggests a possible upside of 16.8% from the stock's current price. View Analyst Price Targets for Array Biopharma.

What is the consensus analysts' recommendation for Array Biopharma?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Array Biopharma in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Array Biopharma.

Has Array Biopharma been receiving favorable news coverage?

Media coverage about ARRY stock has trended positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Array Biopharma earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days.

Who are some of Array Biopharma's key competitors?

What other stocks do shareholders of Array Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Array Biopharma investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), Exelixis (EXEL), Kite Pharma (KITE), United Continental (UAL) and Freeport-McMoRan (Fcx).

Who are Array Biopharma's key executives?

Array Biopharma's management team includes the folowing people:
  • Mr. Ron Squarer, CEO & Director (Age 52)
  • Mr. Jason Haddock, Chief Financial Officer (Age 49)
  • Mr. Andrew R. Robbins, Chief Operating Officer (Age 43)
  • Dr. Victor Sandor, Chief Medical Officer (Age 53)
  • Dr. Nicholas A. Saccomano, Chief Scientific Officer (Age 60)

Who are Array Biopharma's major shareholders?

Array Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Columbus Circle Investors (0.51%), Peregrine Capital Management LLC (0.44%), Rhenman & Partners Asset Management AB (0.28%), Handelsinvest Investeringsforvaltning (0.12%), Boston Advisors LLC (0.04%) and Strs Ohio (0.03%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Carrie Smith Cox, Charles M Baum, Curtis Gale Oltmans, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Nicholas A Saccomano, Ron Squarer and Victor Sandor. View Institutional Ownership Trends for Array Biopharma.

Which major investors are selling Array Biopharma stock?

ARRY stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB, Handelsinvest Investeringsforvaltning and Virtu Financial LLC. Company insiders that have sold Array Biopharma company stock in the last year include Andrew R Robbins, Curtis Gale Oltmans, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Nicholas A Saccomano, Ron Squarer and Victor Sandor. View Insider Buying and Selling for Array Biopharma.

Which major investors are buying Array Biopharma stock?

ARRY stock was acquired by a variety of institutional investors in the last quarter, including Foundry Partners LLC, Pennsylvania Trust Co, Pennsylvania Trust Co, Meeder Asset Management Inc., Boston Advisors LLC, Brinker Capital Inc., Strs Ohio and Mercer Global Advisors Inc. ADV. View Insider Buying and Selling for Array Biopharma.

How do I buy shares of Array Biopharma?

Shares of ARRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array Biopharma's stock price today?

One share of ARRY stock can currently be purchased for approximately $22.92.

How big of a company is Array Biopharma?

Array Biopharma has a market capitalization of $5.00 billion and generates $173.77 million in revenue each year. The biopharmaceutical company earns $-147,340,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Array Biopharma employs 298 workers across the globe.

What is Array Biopharma's official website?

The official website for Array Biopharma is http://www.arraybiopharma.com.

How can I contact Array Biopharma?

Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]


MarketBeat Community Rating for Array Biopharma (NASDAQ ARRY)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  440 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  704
MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Featured Article: Coverage Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel